



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-297/S-027

Abbott Laboratories
Attention: Mary Konkowski
Manager, Global Pharmaceutical
Regulatory Affairs
200 Abbott Park Road
Abbott Park, Ill 60064-6157

Dear Ms Konkowski:

Please refer to your supplemental new drug application dated March 1, 2007, received March 2, 2007, submitted under 505(b) of the Federal Food, Drug, and Cosmetic Act for Ery-Ped (erythromycin ethylsuccinate, USP) Chewable Tablets.

This application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

This supplemental new drug application has been submitted in response to an Agency letter requesting an update to the **WARNINGS and PRECAUTIONS/Information for Patients** sections of the labeling concerning *Clostridium difficile* associated diarrhea.

We completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text in the content of labeling [21CFR 31.50(1)] in structured product labeling FPL format submitted on March 1, 2007.

We note that your March 1, 2007 submission includes final printed labeling (FPL) for your package insert. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured labeling (SPL) format.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Carmen DeBellas, Regulatory Project Manager, at (301) 796-1203.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, M.D.

Acting Director

Division of Anti-Infective and Ophthalmology Products

Office of Antimicrobial Products

Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Wiley Chambers

1/5/2008 03:40:02 PM